Increased expression of survivin in hepatoblastoma after chemotherapy.

Increased expression of survivin in hepatoblastoma after chemotherapy.
复制标题

化疗后肝母细胞瘤中生存素表达增加。

DOI:
10.1055/s-0033-1333637
复制
发表时间:
2013
期刊:
影响因子:
1.8
通讯作者:
Fukuzawa M.
Fukuzawa M.
中科院分区:
医学3区
文献类型:
--
作者:
Uehara S;Oue T;Kawatsu M;Nara K;Fukuzawa M.

文献摘要

相似文献

背景生存素是一种细胞凋亡抑制剂,据报道与某些恶性肿瘤的预后较差有关。然而,其在肝母细胞瘤(HB)中的表达仍有待阐明。我们评估了化疗前后收集的HB标本中survivin的表达,以阐明survivin对HB治疗结果的影响。方法收集16例患者接受2至4个周期的顺铂化疗前后的HB标本。通过免疫组化染色和实时聚合酶链反应评估survivin表达水平。结果化疗前收集的16张HB切片中,免疫组化染色检测12张survivin阳性。发现化疗后生存素表达强度显着增加。令人惊讶的是,化疗后获得的所有 HB 标本均呈生存素阳性。人HB细胞系Huh-6中survivin信使核糖核酸的表达在顺式二氯二氨铂(II)培养时显着高于不加药物培养时。 HB治疗靶点的候选者。
BackgroundSurvivin, an inhibitor of apoptosis, has been reported to be associated with a worse prognosis in some malignancies. However, its expression in hepatoblastoma (HB) remains to be elucidated. We assessed the survivin expression in HB specimens collected before and after chemotherapy to elucidate the impact of survivin on the outcome of HB therapy.MethodsHB specimens were collected before and after 2 to 4 cycles of cisplatin-based chemotherapy from 16 patients. The survivin expression level was assessed by immunohistochemical staining and real-time polymerase chain reaction.ResultsOut of 16, 12 HB sections collected before chemotherapy were positive for survivin as determined by immunohistochemical staining. The intensity of survivin expression was found to significantly increase after chemotherapy. Surprisingly, all of the HB specimens obtained after chemotherapy were positive for survivin. The expression of survivin messenger ribonucleic acid from a human HB cell line, Huh-6 was significantly higher when the cells were cultured with cis-diamminedichloroplatinum(II) than when the cells were cultured without the drug.ConclusionOur results indicate that most of the primary HB tissue specimens express survivin, and its expression increased after chemotherapy, thus suggesting that survivin may concern with the survival of tumor cells, therefore be a candidate for the target of the treatment of HB.